Tirzepatide side effects and safety: a guide for patients in Pakistan

Mounjaro® and TYZEPA are separate branded products. The current official Mounjaro Medication Guide and prescribing information provide useful evidence about tirzepatide and the Lilly product, but they do not prove that TYZEPA has an identical formulation, device, manufacturing quality, clinical performance or side-effect frequency.¹²

Read the patient leaflet supplied with the exact TYZEPA pack and follow the prescriber’s or pharmacist’s advice. Do not transfer Mounjaro dosing, storage or device instructions to TYZEPA. No current primary TYZEPA leaflet was available among the public sources reviewed for this article, so this page does not state TYZEPA-specific frequency estimates.

In the current Mounjaro label, the most common adverse reactions reported in at least 5% of treated patients in the labeling trials are:

• nausea;
• diarrhoea;
• reduced appetite;
• vomiting;
• constipation;
• indigestion; and
• stomach or abdominal pain.

These are not all possible side effects.²⁴ Nausea, vomiting and diarrhoea can become important when they are severe, continue, or prevent adequate fluid intake. Contact your clinician if symptoms persist, worsen, or interfere with eating or drinking. Do not change your dose or dosing interval yourself.

Get emergency medical help now

Possible serious allergic reaction: swelling of the face, lips, tongue or throat; trouble breathing or swallowing; severe rash or itching; fainting or marked dizziness; or a very rapid heartbeat. The Mounjaro guide advises stopping Mounjaro and obtaining medical help immediately.¹ If you use another tirzepatide product, seek emergency care and do not take another dose until a qualified clinician has assessed you.

Severe low blood sugar: confusion, marked drowsiness, fainting, seizure, inability to swallow safely, or symptoms that do not improve with your usual hypoglycaemia plan. The risk is higher when tirzepatide is combined with insulin or a sulfonylurea. Earlier symptoms can include sweating, shaking, dizziness, hunger, blurred vision, weakness, anxiety, headache or a fast heartbeat.

Stop and contact a clinician urgently

Possible pancreatitis: severe, continuing abdominal pain, with or without nausea or vomiting, sometimes spreading to the back. The official Mounjaro information says to stop Mounjaro and call the healthcare provider immediately.¹ For TYZEPA, obtain urgent medical advice before another dose and follow the exact leaflet.

Contact a clinician promptly

• Dehydration or kidney concern: vomiting or diarrhoea that does not stop, inability to keep fluids down, marked dizziness, or much less urine than usual.
• Gallbladder concern: upper abdominal pain, fever, yellow skin or eyes, or pale/clay-coloured stools.
• Severe stomach problem: intense or persistent symptoms, especially with known delayed stomach emptying.
• Eye symptoms: new or worsening vision changes, particularly with diabetic retinopathy.
• Possible thyroid symptoms: a new neck lump or swelling, persistent hoarseness, trouble swallowing, or shortness of breath.

Tirzepatide caused thyroid C-cell tumours in rats. It is unknown whether Mounjaro causes these tumours, including medullary thyroid carcinoma (MTC), in humans. The US Mounjaro label carries a boxed warning and says Mounjaro must not be used in people with a personal or family history of MTC or with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). It is also contraindicated after a known serious hypersensitivity reaction to tirzepatide or a Mounjaro ingredient.²³

This is originator labeling, not evidence that TYZEPA was independently studied in the same way. Anyone considering TYZEPA should disclose MTC, MEN 2, thyroid symptoms and serious drug allergies to the prescriber and check the exact TYZEPA leaflet before use.

Tell your clinician about all medicines, supplements and medical conditions. The originator information highlights previous pancreatic disease; severe gastroparesis or other serious stomach-emptying problems; gallbladder or kidney problems; diabetic retinopathy; insulin or sulfonylurea use; pregnancy or breastfeeding; and planned procedures using general anaesthesia or deep sedation.¹

Tirzepatide delays stomach emptying. The Mounjaro label reports a risk of food or liquid entering the lungs during anaesthesia or deep sedation. Tell the surgeon and anaesthetist that you use tirzepatide and let them decide how to manage it. Do not create your own stopping schedule.

The Mounjaro label also says oral birth-control pills may work less reliably for four weeks after starting treatment and for four weeks after each dose increase. Patients who could become pregnant should ask whether a non-oral method or an additional barrier method is needed, then follow the information for their exact product.

1. Which side effects are most relevant to my health history and medicines?
2. Am I taking insulin or a sulfonylurea that raises my hypoglycaemia risk?
3. Do my thyroid, pancreatic, gallbladder, kidney, eye or stomach conditions change suitability?
4. Which symptoms mean I should stop and seek urgent care?
5. What should I do before surgery, endoscopy or sedation?
6. Which leaflet applies to my exact brand, strength and presentation?
7. How should I report a suspected side effect or quality problem in Pakistan?

Patients and caregivers can report suspected medicine side effects to the National Pharmacovigilance Centre at DRAP. Keep the brand, strength, batch number, dose, dates and pack photographs available.⁵⁶ Reporting supports safety monitoring; it does not by itself prove that the medicine caused the event.

This page is general education and not a complete list of adverse effects. If the exact leaflet is missing, damaged or inconsistent with the pack, do not guess; ask a qualified pharmacist before use.